These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 328950)

  • 21. Amikacin therapy for serious gram-negative bacillary infections.
    Meyer RD; Lewis RP; Carmalt ED; Finegold SM
    Ann Intern Med; 1975 Dec; 83(6):790-800. PubMed ID: 1200524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prudent use of the aminoglycosides.
    Gregory D; Hirschmann JV
    Postgrad Med; 1978 Sep; 64(3):97-102, 104. PubMed ID: 704499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects].
    Romoli E; Di Leonardo F; Giordano G; De Felice M; Cerquetti F; Vonmoos A
    Minerva Urol; 1981; 33(2):85-90. PubMed ID: 7322100
    [No Abstract]   [Full Text] [Related]  

  • 24. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of pediatric infections with amikacin as first-line aminoglycoside.
    Shulman ST; Yogev R
    Am J Med; 1985 Jul; 79(1A):43-50. PubMed ID: 4025367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside.
    King JW; White MC; Todd JR; Conrad SA
    Clin Infect Dis; 1992 Apr; 14(4):908-15. PubMed ID: 1576287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
    Moellering RC; Wennersten C; Kunz LJ; Poitras JW
    Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical pharmacology of the most frequently used aminoglucosides: gentamycin, tobramycin and amikacin].
    Cuena Boy R; Azanza Perea JR; Echeverría Echepare LM; Honorato Pérez J
    Rev Med Univ Navarra; 1983 Dec; 27(4):21-7. PubMed ID: 6676898
    [No Abstract]   [Full Text] [Related]  

  • 29. Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results.
    Daikos GK; Kosmidis JC; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S286-90. PubMed ID: 993623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, randomized study of amikacin and gentamicin in serious infections with focus on efficacy, toxicity and duration of serum levels above the MIC.
    Holm SE; Hill B; Löwestad A; Maller R; Vikerfors T
    J Antimicrob Chemother; 1983 Oct; 12(4):393-402. PubMed ID: 6643334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin.
    Edson RS; Terrell CL
    Mayo Clin Proc; 1987 Oct; 62(10):916-20. PubMed ID: 3657309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of amikacin in treatment of infections due to gram-negative aerobic bacilli.
    Mathias RG; Ronald AR; Gurwith MJ; McCullough DW; Stiver HG; Berger J; Cates CY; Fox LM; Lank BA
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-401. PubMed ID: 825590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W; Reindke B; Versmold H
    J Infect Dis; 1976 Nov; 134 SUPPL():S412-9. PubMed ID: 825592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective comparative study of efficacy and toxicity of netilmicin and amikacin.
    Bock BV; Edelstein PH; Meyer RD
    Antimicrob Agents Chemother; 1980 Feb; 17(2):217-25. PubMed ID: 6992711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns and mechanisms of emergence of resistance to amikacin.
    Meyer RD
    J Infect Dis; 1977 Sep; 136(3):449-52. PubMed ID: 409785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amikacin treatment of pulmonary infections involving gentamicin-resistant gram-negative bacilli.
    Bartlett JG
    Am J Med; 1977 Jun; 62(6):945-8. PubMed ID: 868911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gentamicin, tobramycin, amikacin, and netilmicin levels in tears following intravenous administration.
    Woo FL; Johnson AP; Insler MS; George WJ; LaCorte WS
    Arch Ophthalmol; 1985 Feb; 103(2):216-8. PubMed ID: 3977692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative in vitro activity of netilmicin, amikacin, tobramycin and sisomicin against gentamicin highly-resistant enterobacteriaceae.
    Tselentis J; Legakis NJ; Nicolas KJ; Melissinos K; Papavassiliou J
    Chemotherapy; 1980; 26(6):409-17. PubMed ID: 7408554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of netilmicin, gentamicin, tobramycin and amikacin against glucose fermenting and nonfermenting bacteria.
    DiPersio JR; Krafczyk TL
    Chemotherapy; 1980; 26(5):323-33. PubMed ID: 7389428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.